A Non-Interventional Trial of Xeloda in Metastatic Colorectal Cancer, Adjuvant Colon Cancer, Advanced Gastric Cancer and Breast Cancer
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 563
- 主要终点
- Number of Participants With Routine Clinical Use of Capecitabine as Per the Line of Treatment
研究概览
简要总结
This multi-center observational study will evaluate the use of Xeloda (capecitabine) in patients with metastatic colorectal cancer, colon cancer in the adjuvant setting, advanced gastric cancer and breast cancer in routine clinical practice. Eligible patients receiving treatment with Xeloda according to product label will be followed for up to 10 months.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with metastatic colorectal cancer, colon cancer in the adjuvant setting, advanced gastric cancer or breast cancer who are candidates for receiving Xeloda according to product label
排除标准
- •Contraindications according to label and off-label use
研究组 & 干预措施
Capecitabine
Participants will receive capecitabine according to the label text as monotherapy (1250 mg/m^2 twice daily) or combination therapy (800 to 1000 mg/m^2 or 1250 mg/m^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
干预措施: Capecitabine (Drug)
结局指标
主要结局
Number of Participants With Routine Clinical Use of Capecitabine as Per the Line of Treatment
时间窗: Approximately 3 years; or up to disease progression, death or stop of capecitabine treatment, whichever occurred first
Choice of line of treatment in adjuvant and advanced or metastatic cancer for capecitabine was observed.
次要结局
- Median Dose of Capecitabine(Approximately 3 years; or up to disease progression, death or stop of capecitabine treatment, whichever occurred first)